Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-arm study at St. Jude Children's Research Hospital will image pediatric patients receiving proton therapy for solid tumors or Hodgkin lymphoma to detect anatomical changes during treatment. Weekly or biweekly CT scans, with MRI as appropriate, will assess whether the original plan still provides adequate tumor coverage and protects normal tissues. A plan rework will be performed if tumor coverage drops by more than 5% or if normal-tissue dose increases by 10% or more; otherwise the initial plan remains in use. The goal is to quantify how often replanning is needed and identify disease sites with the most frequent changes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants diagnosed with solid tumors, including Rhabdomyosarcoma, Osteosarcoma, Ewing sarcoma, other sarcomas and carcinomas or also Hodgkin's lymphoma.
* Participants who receive proton radiation therapy at St. Jude Children's Research Hospital.
* Research participant or legal guardian/representative gives written informed consent.

Exclusion Criteria:

* Participants who are not diagnosed with solid tumors or Hodgkin's lymphoma.
* Participants who are diagnosed with Wilm's tumor or neuroblastoma
* Participants who do not undergo proton therapy.
* Participants who are prescribed equal or less than 5 fractions of proton therapy.
* Participants with severe comorbid conditions that may impact imaging feasibility.
* Inability to obtain written consent from research participant or legal guardian/representative.
* Females of child-bearing potential cannot be pregnant or breast-feeding. Female participants \>10 years of age or post-menarchal must have a negative serum or urine pregnancy test

All participants receiving proton therapy at St. Jude Children's Research Hospital will be screened for participation on this research protocol based on the Inclusion Criteria and the Exclusion Criteria. Qualified candidates will be selected during the consultation.

Where it's running

• St. Jude Children's Research Hospital
  Memphis, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Ozgur Ates, PhD — St. Jude Children's Research Hospital
• Study coordinator: Ozgur Ates, PhD
• Email: referralinfo@stjude.org
• Phone: 888-226-4343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Using HER2 CAR T cells with checkpoint inhibitors for advanced sarcoma

  This study is testing a new treatment that combines personalized CAR T cells with immune boosters to see if it helps people with advanced HER2-positive sarcoma.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT04995003

• B7-H3 CAR T-cell therapy for pediatric solid tumors

  This study is testing a new type of immune therapy using specially modified T cells to see if it can help children with tough-to-treat solid tumors.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT04897321

• Transplantation with modified stem cells and Zoledronate for pediatric cancers

  This study is testing a new way to use modified stem cells and a drug called Zoledronate to see if it can safely help children with tough-to-treat cancers.

  Recruiting Phase 1 University of Wisconsin, Madison · Madison, Wisconsin · NCT02508038

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• Using silmitasertib with chemotherapy for relapsed solid tumors

  This study is testing a new drug called silmitasertib combined with chemotherapy to see if it helps people with relapsed solid tumors feel better and manage their cancer.

  Recruiting at 24 sites Phase 1/2 Milton S. Hershey Medical Center · Birmingham, Alabama and 23 other locations · NCT06541262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.